Paola Patrignani
Annalisa Contursi1,2
Stefania Tacconelli
Dieter Steinhilber- 1Systems Pharmacology and Translational Therapeutics Laboratory, The Center for Advanced Studies and Technology (CAST), “G. d’ Annunzio” University, Chieti, Italy
- 2Department of Neuroscience, Imaging and Clinical Science, “G. d Annunzio” University Medical School, Chieti, Italy
- 3Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany
Many drugs can act on multiple targets or disease pathways, regardless of their original purpose. Drug repurposing involves reevaluating existing compounds for new medical uses. This can include repositioning approved drugs, redeveloping unapproved drugs, or repurposing any chemical, nutraceutical, or biotherapeutic product for new applications. Traditional drug development is slow, expensive, and has high failure rates. Drug repurposing can speed up the process, costing less and saving time. This approach can save 6–7 years of early-stage research time. Drug repurposing benefits from existing compounds with optimized structures and approved for clinical use with associated structure-activity relationship publications, supporting the development of new effective compounds. Drug repurposes can now utilize advanced in silico screening enabled by artificial intelligence (AI) and sophisticated tissue and organ-level in vitro models. These models more accurately replicate human physiology and improve the selection of existing drugs for further pre-clinical testing and, eventually, clinical trials for new indications. This mini-review discusses some examples of drug repurposing and novel strategies for further development of compounds for targets of the arachidonic acid cascade. In particular, we will delve into the prospect of repurposing antiplatelet agents for cancer prevention and addressing the emerging noncanonical functionalities of 5-lipoxygenase, potentially for leukemia therapy.
1 Introduction
The future of pharmacology and therapeutics in the next decade depends on several crucial factors, such as the discovery of new drug targets, the evolution of drug delivery systems, and the refinement of precision tools for personalized medicine. A debate centers around whether we should focus on developing new drugs to treat human diseases or if it is better to repurpose existing compounds by enhancing our understanding of their mechanisms of action using new tools such as omics technology and artificial intelligence. It is important to note that current cancer treatments have significant toxicity and can significantly impact patients’ lives, even if they provide a few extra years of life. This underscores the need for effective drug delivery systems and personalized patient treatment. However, our current tools for characterizing patients’ clinical backgrounds and individual responses to treatments still need to be optimized. This mini-review focuses on effective strategies for reducing the time and cost of drug development by drug repurposing (or repositioning) for targets of the arachidonic acid cascade, which allows the identification of new therapeutic applications of already approved drugs. We will explore specific examples of drug repurposing and innovative strategies for further advancement in the field. Thus, we focus on the potential use of antiplatelet agents for cancer prevention and examine the discovery of noncanonical roles of 5-lipoxygenase (5-LO), particularly in the context of therapy for leukemia.
2 Repurposing antiplatelet agents in cancer prevention
De Angelis et al. (2024) recently reported that in 2020, 23.7 million people in Europe (12.8 million women and 10.9 million men) had been diagnosed with cancer at some point in their lives, either recently or in the past. This accounts for 5% of the population, which is expected to increase as the population ages. The high cost of innovative therapies and an aging population are challenging the sustainability of healthcare and social systems. Therefore, it is crucial to prioritize primary prevention and early diagnosis to reduce the number of patients and improve the chances of recovery.
A large-scale study carried out in the United States found that removing colorectal adenoma as a precancerous lesion can reduce the risk of death from colorectal cancer by 53% (Zauber et al., 2012). Therefore, endoscopic resection is performed globally for the treatment of colorectal adenomas. For pre-colectomy and post-colectomy patients, chemoprevention aims to prevent or slow down the growth of adenomas. This can lower the risk of cancer development, thus reducing the need for surgery and delaying the need for surveillance endoscopy. Adding low-dose aspirin can be an effective and cost-efficient strategy because it prevents proximal colorectal adenomas (Hassan et al., 2012).
There is compelling evidence that low-dose aspirin could inhibit the initial stages of colorectal adenoma development, resulting in long-term colorectal adenoma and cancer prevention (Patrignani and Patrono, 2016). Low-dose aspirin is an antiplatelet drug that mainly affects the biosynthesis of platelet thromboxane (TX)A2 by irreversibly affecting the activity of cyclooxygenase (COX)-1. TXA2 has biologically relevant roles in hemostasis (including platelet aggregation), vascular tone (contraction of vascular smooth muscle cells, VSMC), cell proliferation, and migration. TXA2 regulates the tumor microenvironment by modulating angiogenic potential, tumor extracellular matrix (ECM) stiffness, and host immune response (Ashton et al., 2022). Thus, it has been proposed that aspirin can limit the development of colorectal tumors by affecting platelet-dependent signaling pathways triggered during the early stages of colorectal adenomatous lesion development (Patrignani and Patrono, 2016; 2018) (Figure 1). Our recent findings support this hypothesis (Bruno et al., 2022). ApcMin/+ mice (an animal model bearing multiple intestinal neoplasia) with the specific deletion of Ptgs1 (protein name COX-1) in the megakaryocytes/platelets (mimicking the pharmacodynamics of low-dose aspirin in humans) were associated with a reduced number (67%) and size (29%) of tumors of the small intestine (Bruno et al., 2022). One of the first events in developing intestinal adenomatous lesions is the induction of COX-2 in myofibroblasts, leading to enhanced biosynthesis of prostaglandin (PG)E2, which is a crucial pathway in cancer as it prevents apoptosis while promoting migration, proliferation, angiogenesis, and immune evasion (Wang and Dubois, 2010; 2014). Extravasated platelets are detected in conjunction with myofibroblasts in the inflamed colon (Sacco et al., 2019) and in intestine tissue sections of ApcMin/+mice (Bruno et al., 2022). The release of platelet TXA2 activates myofibroblast TXA2 receptors (TP) involved in COX-2 expression, enhances proliferative and migratory abilities, and expression of mesenchymal markers such as vimentin in myofibroblasts (Bruno et al., 2022; Sacco et al., 2019).
Figure 1. The platelet hypothesis of tumorigenesis and mechanisms of antitumor effects of antiplatelet agents and anti-inflammatory drugs. In the early stages of tumor formation, activated platelets release growth and angiogenic factors, thromboxane (TX) A2 and adenosine diphosphate (ADP), which contribute to the development of an inflammatory microenvironment via the induction of COX-2 (cyclooxygenase-2) expression leading to aberrant generation to prostaglandin (PG) E2. PGE2 is a central mediator in inflammation and contributes to acquiring tumor properties, such as proliferation, inhibition of apoptosis, migration, and immune escape. These processes promote the growth and survival of early tumor cells. Tumor progression is associated with immune infiltration, extravasated platelets, and enhanced PGE2 and TXA2 generation that contribute to immune escape. In advanced tumors, COX-2-dependent PGE2 contributes to epithelial-mesenchymal transition (EMT). In the bloodstream, platelets interact with cancer cells, enabling them to spread and colonize other tissues through various mechanisms, including EMT. Antiplatelet agents like aspirin and clopidogrel, by inhibiting platelet activation, prevent the induction of COX-2 and PGE2, thus affecting early tumor development. Moreover, antiplatelet agents constrain tumor progression and metastasis. Anti-inflammatory drugs, such as coxibs (selective COX-2 inhibitors), can impede cancer development, progression and metastasis by inhibiting the activity of COX-2.
Aspirin can indirectly prevent the upregulation of COX-2-dependent signaling pathways that promote cancer development by affecting platelet function (Patrignani and Patrono, 2016; 2018). Rodríguez-Miguel et al. (2019) performed an epidemiologic study on the association between Clopidogrel intake, another antiplatelet agent acting by preventing the activation of the P2Y12 receptor for ADP, alone or associated with aspirin, and colorectal cancer (CRC) incidence using a large population-based database of electronic health records in Spain. The authors found that clopidogrel intake has a similar effect on CRC as low-dose aspirin. However, the mechanism of these protective effects remains to be elucidated. Notably, the possible improved cancer prevention by the coadministration of low-dose aspirin and a P2Y12 antagonist (dual antiplatelet therapy) remains to be clarified. Clopidogrel, one of the ADP receptor antagonist family, is recommended for the reduction of atherosclerotic events, including myocardial infarction, ischemic stroke, and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction, or established peripheral vascular disease (Jarvis and Simpson, 2000). Clopidogrel is available as a generic medication. Retrospective database analysis has shown that generic clopidogrel is comparable to its brand-name counterpart regarding cardiovascular and bleeding outcomes for treating patients with acute myocardial infarction (Chan et al., 2023). Both low-dose aspirin and clopidogrel used as monotherapy enhance, to a comparable extent, the risk of upper gastrointestinal bleeding (García Rodríguez et al., 2011). However, the risk of upper gastrointestinal bleeding is relatively low for individuals under 70 years of age.
ADP is an important platelet agonist that is actively secreted from platelet-dense granules but is also passively released from damaged erythrocytes, endothelial cells, and apoptotic cancer cells (Woulfe et al., 2001). Along with TXA2, it amplifies platelet functions, and there is an important interplay between the two in promoting platelet activation in response to low concentrations of primary agonists such as collagen and thrombin (Tacconelli et al., 2020). Platelets store a significant amount of proteins in α-granules, including angiogenic, inflammatory, and growth factors released upon activation by specific signaling pathways (Quinton et al., 2004). ADP-induced α-granule release through costimulation of Gαq and Gαi signaling. The TXA2 receptor, which signals via Gα12/13 and Gαq, requires the P2Y12 receptor Gαi signal for α-granule release. Hence, blocking the P2Y12 receptor is more effective than aspirin in inhibiting protein release from platelet α-granules. We have discovered that when platelets and cancer cells are cultured together, inhibiting platelet COX-1 using aspirin or blocking the P2Y12 receptor with antagonists can prevent the platelet-induced epithelial-mesenchymal transition (EMT) phenomenon and migration of cancer cells in vitro (Guillem-Llobat et al., 2016). These events are critical factors in cancer metastasis. This response is associated with inhibition of platelet activation and reduced generation of TXA2 and PGE2, which are involved in EMT. Furthermore, our research has revealed that extracellular vesicles (EVs) derived from platelets of CRC patients are implicated in acquiring prothrombotic phenotypes in cancer cells (Contursi et al., 2023). The increase in the generation of TXA2 in cancer cells mediates this process. In addition, bound platelets or platelet aggregates may enhance the survival of circulating tumor cells by protecting them from immune destruction or physical damage caused by shear stress in the microcirculation. As a result, curbing or inhibiting platelet activation in cancer patients may mitigate metastasis, and individuals at risk of cancer-associated thrombosis might benefit from that treatment (Wright et al., 2020).
Of note, aspirin and clopidogrel are both irreversibly acting drugs. Aspirin acetylates both COX isoforms at a serine residue in the active site (Roth et al., 1975), whereas clopidogrel forms a disulfide bridge with extracellular cysteines of the P2Y12 receptor (Savi et al., 2000; Ding et al., 2003). In contrast to noncovalent binding mechanisms, this mode of action requires de novo synthesis of the target protein to restore protein activity, and the duration of drug action usually mainly depends on the half-life of the target protein in the respective cell. In platelets, there is limited de novo protein biosynthesis, so there is a sustained action of irreversibly binding drugs, which correlates with the lifespan of platelets of around 10 days. Thus, irreversible inhibitors are very effective in the inhibition of platelet-derived proteins. In the case of aspirin, this leads to sustained and effective inhibition of TXA2 formation in platelets, whereas prostaglandin formation in other cell types is less affected by low-dose aspirin. Some clinical trials are ongoing and are assessing the impact of low-dose aspirin in cancer prevention, such as CAPP3 in Lynch syndrome (https://www.capp3.org/) and the Add aspirin trial in four types of cancer (colorectal, breast, prostate, and esophageal cancer) (Coyle et al., 2016). New trials will be designed to assess the impact of clopidogrel and other P2Y12 inhibitors in adenoma prevention in patients with sporadic cancer. The importance of dual antiaggregatory inhibition by the two drugs to improve anticancer efficacy remains to be investigated.
3 Developing a systems biology approach and network analysis to explore deregulated biological processes and identify potential drug-repurposing candidates
Network-based analysis is an established method for in silico examination of the intricate nature of biological systems and assessing interactions among the various participants. This approach serves as a robust instrument for correlating pharmacological and disease data. Recent systems biology methodologies, leveraging network analysis, have explored novel applications for existing drugs, anticipated potential new anticancer therapeutic avenues, and pinpointed promising targets for further investigation. Here, we report some examples of this approach.
The biological response to disease, inflammation, is critical to many pathological states. Managing inflammation with drugs is crucial in medical practice. Anti-inflammatory drugs work by targeting specific molecules involved in the inflammatory response. These drugs are typically classified as steroidal and non-steroidal. However, their effects often extend beyond their intended targets, impacting other molecules and biological functions, which can result in secondary therapeutic applications or adverse drug reactions (ADRs). Using network models, a recent study (de Anda-Jáuregui et al., 2018) explored relationships among anti-inflammatory drugs, functional pathways, and ADRs. The study used network-based properties such as degree, clustering coefficient, and node strength to identify new therapeutic applications and ADR risks for these drugs. These parameters have identified naproxen, meloxicam, etodolac, tenoxicam, flufenamic acid, fenoprofen, and nabumetone as potential candidates for drug repurposing due to their lower ADR risk. This network-based analysis offers a new approach to examining the impact of drugs in a therapeutic setting.
Metabolic syndrome is a complex condition characterized by the combined occurrence of obesity, high blood sugar levels, elevated blood pressure, increased concentrations of triglycerides, and decreased levels of high-density lipoprotein cholesterol. A systems biology approach employing network analysis has been utilized to investigate the biological processes associated with the syndrome and explore potential drug treatments (Misselbeck et al., 2019). The approach suggests that the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib could be a novel pharmacological treatment, as it effectively lowers inflammation in an obesity model. BTK inhibitors impede the activity of the enzyme BTK, a critical component within the B-cell receptor signaling pathway. Specific B-cell leukemias and lymphomas rely on B-cell receptor signaling to promote their growth and survival.
4 5-Lipoxygenase and cancer
The 5-LO pathway was discovered in the seventies of the last century (Borgeat et al., 1976). It was observed that arachidonic acid (AA) is oxidized at carbon C(5), which finally leads to the generation of leukotrienes (LT) where 5-LO acts in concert with the down-stream leukotriene synthases LTA4 hydrolase and LTC4 synthase (Samuelsson, 1987). Studies on the biological roles of these lipid mediators have uncovered that LTs are mediators of inflammatory and allergic responses, that they play a role in the innate immune system, and are involved in host defense reactions (Peters-Golden and Henderson, 2007; Flamand et al., 2007; Serenzani et al., 2023). Due to the pro-inflammatory functions of LTs and other 5-LO-derived oxylipins, 5-LO became an interesting target for inhibitor development. However, none of the 5-LO and FLAP inhibitors reached the market except for zileuton. One possible explanation is that the sole inhibition of 5-LO and LT formation is not effective enough to treat inflammatory diseases (Sala et al., 2018). Apart from its role in inflammation, the involvement of 5-LO in cancer development has been suggested by many studies in different tissues (for review, see Steinhilber et al., 2010). For BCR-ABL-positive leukemia in mice, it was shown that knockout of 5-LO prevents CML induction, which seems to be due to a defect in leukemic stem cell proliferation and long-term survival in the absence of 5-LO (Chen et al., 2009). Treatment with high doses of the 5-LO inhibitor zileuton had the same effect (Chen et al., 2009). In line with this, we could show that pharmacological inhibition of 5-LO by CJ-13,610 also affects the aberrant stem cell capacity in a PML/RARα-positive model of AML (acute myeloid leukemia) and a murine cancer stem cell (CSC) model (Roos et al., 2014). The specific mechanisms accountable for these effects are not wholly understood. One observation was that certain 5-LO inhibitors prevent the translocation of beta-catenin into the nucleus and thus inhibit Wnt-signalling, which regulates the stemness of myeloid progenitor cells (Roos et al., 2014). The interaction of 5-LO with beta-catenin is supported by proximity ligation assays, which demonstrated the cellular co-localization of 5-LO and beta-catenin and the inhibition of beta-catenin translocation into the nucleus with the 5-LO inhibitors (Brand et al., 2018; Roos et al., 2014). Although the mode of interaction between 5-LO and beta-catenin is unclear at the moment, the inhibitor experiments and the proximity ligation assays suggest that both proteins might be located in the same protein complex. Of note, depending on its role in cellular responses, 5-LO can be localized at different intracellular sites. In resting cells, the protein can be present in the cytosol or the nucleus within euchromatin, whereas inflammatory stimuli lead to the translocation of 5-LO to the nuclear membrane, where it interacts with FLAP for LT formation. Recently, it was shown that the nuclear localization of 5-LO in leukocytes is related to a noncanonical function as a regulator of gene expression, which seems to be independent of the classical enzymatic activity (Kreiß et al., 2022). Among many others, COX-2 and kynureninase (i.e., an enzyme responsible for the formation of 3-OH-anthranilic acid) were identified as direct 5-LO target genes, and pathway analyses revealed that many genes involved in the regulation of inflammatory responses, cell adhesion, and cell proliferation are regulated by 5-LO. The interaction of 5-LO with dicer is another noncanonical function of the 5-LO protein (Provost et al., 1999). Recently, we have shown that 5-LO induces the expression of the miR-99b/let-7e/125a cluster at the pri-miR level but inhibits the processing of pre-let-7e by dicer so that 5-LO upregulates expression of the mature miR-99b as well as miR-125a whereas the cellular let-7e levels are kept constant (Uebbing et al., 2021). This is particularly interesting as these miRNAs regulate myeloid cell differentiation and play an important role in tumorigenesis and developmental processes. Thus, apart from its key role in oxylipin formation, 5-LO has several noncanonical functions which seem to be at least partially independent of its classical enzymatic activity and which are not affected by the classical 5-LO inhibitors (Kahnt et al., 2024). Thus, it might be interesting to target these noncanonical 5-LO functions by developing new inhibitors and, therefore, to address cell adhesion and developmental processes, which might be helpful for leukemia treatment. Since 5-LO is mainly expressed in leukocytes, this approach would allow for the specific interference of signaling processes in these blood cell types.
5 Conclusion
Drug repurposing, also called repositioning or reprofiling, identifies new uses for approved or investigational drugs. This can result from accidental discoveries of off-target effects or newly recognized actions. For example, thalidomide, withdrawn from the market due to birth defects, was later repurposed to treat leprosy and multiple myeloma. During the HIV/AIDS crisis, the drug azidothymidine (AZT), originally developed to treat certain cancers, was repurposed as a potent anti-HIV compound. This effort quickly advanced from lab testing to clinical use, with FDA approval in 1987 for managing HIV. During the COVID-19 pandemic, drug repurposing has progressed rapidly, with over 100 drugs moved into clinical trials for COVID-19 between January 2020 and December 2021. Four drugs have received FDA approval or emergency use authorization, and an additional 15 drugs have been recommended for off-label use. This approach enables faster development during emergencies, reduces safety risks and costs, and could lead to discovering new targets for novel therapeutics. The potential of drug repurposing for commercial use has been hindered by patent and market challenges. However, there is increasing interest from clinicians, foundations, and government agencies, driven by the need for quick patient solutions and preparedness for pandemics. Drug repurposes can now utilize advanced in silico screening enabled by AI and sophisticated tissue and organ-level in vitro models. These models more accurately replicate human physiology, improving the selection of existing drugs for further pre-clinical testing and clinical trials for new indications.
Author contributions
PP: Writing–review and editing, Writing–original draft, Funding acquisition, Formal Analysis. AC: Writing–review and editing, Formal Analysis. ST: Writing–review and editing, Formal Analysis. DS: Writing–review and editing, Writing–original draft, Formal Analysis, Funding acquisition.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This review was funded by Associazione Italiana per la Ricerca sul Cancro (AIRC) [under IG 2017- ID. 20365 Project; Principal Investigator Paola Patrignani]. In addition, this work was conducted on behalf of the Aspirin for Cancer Prevention Group, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine and Dentistry, University of London (United Kingdom). Moreover, it was funded by the European Union - European Social Fund - PON Research and Innovation 2014–2020 to Annalisa Contursi and Dieter Steinhilber was supported by the Deutsche Forschungsgemeinschaft (SFB 1039, TP A02).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ashton, A. W., Zhang, Y., Cazzolli, R., and Honn, K. V. (2022). The role and regulation of thromboxane A2 signaling in cancer-trojan horses and misdirection. Molecules 27 (19), 6234. doi:10.3390/molecules27196234
Borgeat, P., Hamberg, M., and Samuelsson, B. (1976). Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J. Biol. Chem. 251 (24), 7816–7820. doi:10.1016/s0021-9258(19)57008-9
Brand, S., Roy, S., Schröder, P., Rathmer, B., Roos, J., Kapoor, S., et al. (2018). Combined proteomic and in silico target identification reveal a role for 5-lipoxygenase in developmental signaling pathways. Cell Chem. Biol. 25 (9), 1095–1106. doi:10.1016/j.chembiol.2018.05.016
Bruno, A., Contursi, A., Tacconelli, S., Sacco, A., Hofling, U., Mucci, M., et al. (2022). The specific deletion of cyclooxygenase-1 in megakaryocytes/platelets reduces intestinal polyposis in ApcMin/+ mice. Pharmacol. Res. 185, 106506. doi:10.1016/j.phrs.2022.106506
Chan, C. C., Tung, Y. C., Lee, K. T., Chan, Y. H., and Chu, P. H. (2023). Clinical outcomes of generic versus brand-name clopidogrel for secondary prevention in patients with acute myocardial infarction: a nationwide cohort study. Clin. Transl. Sci. 16 (9), 1594–1605. doi:10.1111/cts.13590
Chen, Y., Hu, Y., Zhang, H., Peng, C., and Li, S. (2009). Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 41 (7), 783–792. doi:10.1038/ng.389
Contursi, A., Fullone, R., Szklanna-Koszalinska, P., Marcone, S., Lanuti, P., Taus, F., et al. (2023). Tumor-educated platelet extracellular vesicles: proteomic profiling and crosstalk with colorectal cancer cells. Cancers (Basel) 15 (2), 350. doi:10.3390/cancers15020350
Coyle, C., Cafferty, F. H., Rowley, S., MacKenzie, M., Berkman, L., Gupta, S., et al. (2016). ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp. Clin. Trials 51, 56–64. doi:10.1016/j.cct.2016.10.004
de Anda-Jáuregui, G., Guo, K., McGregor, B. A., and Hur, J. (2018). Exploration of the anti-inflammatory drug space through network pharmacology: applications for drug repurposing. Front. Physiol. 9, 151. doi:10.3389/fphys.2018.00151
De Angelis, R., Demuru, E., Baili, P., Troussar, X., Katalinic, A., Chirlaque Lopz, M. D., et al. (2024). Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol. 25 (3), 293–307. doi:10.1016/S1470-2045(23)00646-0
Ding, Z., Kim, S., Dorsam, R. T., Jin, J., and Kunapuli, S. P. (2003). Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101 (10), 3908–3914. doi:10.1182/blood-2002-10-3027
Flamand, N., Mancuso, P., Serezani, C. H., and Brock, T. G. (2007). Leukotrienes: mediators that have been typecast as villains. Cell Mol. Life Sci. 64 (19-20), 2657–2670. doi:10.1007/s00018-007-7228-2
García Rodríguez, L. A., Lin, K. J., Hernández-Díaz, S., and Johansson, S. (2011). Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 123 (10), 1108–1115. doi:10.1161/CIRCULATIONAHA.110.973008
Guillem-Llobat, P., Dovizio, M., Bruno, A., Ricciotti, E., Cufino, V., Sacco, A., et al. (2016). Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget 7 (22), 32462–32477. doi:10.18632/oncotarget.8655
Hassan, C., Rex, D. K., Cooper, G. S., Zullo, A., Launois, R., and Benamouzig, R. (2012). Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. Gut 61 (8), 1172–1179. doi:10.1136/gutjnl-2011-300206
Jarvis, B., and Simpson, K. (2000). Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 60 (2), 347–377. doi:10.2165/00003495-200060020-00012
Kahnt, A. S., Häfner, A. K., and Steinhilber, D. (2024). The role of human 5-Lipoxygenase (5-LO) in carcinogenesis - a question of canonical and noncanonical functions. Oncogene 43 (18), 1319–1327. doi:10.1038/s41388-024-03016-1
Kreiß, M., Oberlis, J. H., Seuter, S., Bischoff-Kont, I., Sürün, D., Thomas, D., et al. (2022). Human 5-lipoxygenase regulates transcription by association to euchromatin. Biochem. Pharmacol. 203, 115187. doi:10.1016/j.bcp.2022.115187
Misselbeck, K., Parolo, S., Lorenzini, F., Savoca, V., Leonardelli, L., Bora, P., et al. (2019). A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome. Nat. Commun. 10 (1), 5215. doi:10.1038/s41467-019-13208-z
Patrignani, P., and Patrono, C. (2016). Aspirin and cancer. J. Am. Coll. Cardiol. 68 (9), 967–976. doi:10.1016/j.jacc.2016.05.083
Patrignani, P., and Patrono, C. (2018). Aspirin, platelet inhibition and cancer prevention. Platelets 29 (8), 779–785. doi:10.1080/09537104.2018.1492105
Peters-Golden, M., and Henderson, W. R. (2007). Leukotrienes. N. Engl. J. Med. 357 (18), 1841–1854. doi:10.1056/NEJMra071371
Provost, P., Samuelsson, B., and Rådmark, O. (1999). Interaction of 5-lipoxygenase with cellular proteins. Proc. Natl. Acad. Sci. U. S. A. 96 (5), 1881–1885. doi:10.1073/pnas.96.5.1881
Quinton, T. M., Murugappan, S., Kim, S., Jin, J., and Kunapuli, S. P. (2004). Different G protein-coupled signaling pathways are involved in alpha granule release from human platelets. J. Thromb. Haemost. 2 (6), 978–984. doi:10.1111/j.1538-7836.2004.00741.x
Rodríguez-Miguel, A., García-Rodríguez, L. A., Gil, M., Montoya, H., Rodríguez-Martín, S., and de Abajo, F. J. (2019). Clopidogrel and low-dose aspirin, alone or together, reduce risk of colorectal cancer. Clin. Gastroenterol. Hepatol. 17 (10), 2024–2033. doi:10.1016/j.cgh.2018.12.012
Roos, J., Oancea, C., Heinssmann, M., Khan, D., Held, H., Kahnt, A. S., et al. (2014). 5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia. Cancer Res. 74 (18), 5244–5255. doi:10.1158/0008-5472.CAN-13-3012
Roth, G. J., Stanford, N., and Majerus, P. W. (1975). Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. U. S. A. 72 (8), 3073–3076. doi:10.1073/pnas.72.8.3073
Sacco, A., Bruno, A., Contursi, A., Dovizio, M., Tacconelli, S., Ricciotti, E., et al. (2019). Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 370 (3), 416–426. doi:10.1124/jpet.119.259382
Sala, A., Proschak, E., Steinhilber, D., and Rovati, G. E. (2018). Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade. Biochem. Pharmacol. 158, 161–173. doi:10.1016/j.bcp.2018.10.007
Samuelsson, B. (1987). An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes. Drugs 33 (Suppl. 1), 2–9. doi:10.2165/00003495-198700331-00003
Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., et al. (2000). Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84 (5), 891–896. doi:10.1055/s-0037-1614133
Serezani, C. H., Divangahi, M., and Peters-Golden, M. (2023). Leukotrienes in innate immunity: still underappreciated after all these years? J. Immunol. 210 (3), 221–227. doi:10.4049/jimmunol.2200599
Steinhilber, D., Fischer, A. S., Metzner, J., Steinbrink, S. D., Roos, J., Ruthardt, M., et al. (2010). 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front. Pharmacol. 24 (1), 143. doi:10.3389/fphar.2010.00143
Tacconelli, S., Fullone, R., Dovizio, M., Pizzicoli, G., Marschler, S., Bruno, A., et al. (2020). Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1865 (12), 158804. doi:10.1016/j.bbalip.2020.158804
Uebbing, S., Kreiß, M., Scholl, F., Häfner, A. K., Sürün, D., Garscha, U., et al. (2021). Modulation of microRNA processing by 5-lipoxygenase. FASEB J. 35 (2), e21193. doi:10.1096/fj.202002108R
Wang, D., and Dubois, R. N. (2010). Eicosanoids and cancer. Nat. Rev. Cancer 10 (3), 181–193. doi:10.1038/nrc2809
Wang, D., and Dubois, R. N. (2014). An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J. 19, 502–510. doi:10.1097/PPO.0000000000000003
Woulfe, D., Yang, J., and Brass, L. (2001). ADP and platelets: the end of the beginning. J. Clin. Invest 107 (12), 1503–1505. doi:10.1172/JCI13361
Wright, J. R., Chauhan, M., Shah, C., Ring, A., Thomas, A. L., Goodall, A. H., et al. (2020). The TICONC (Ticagrelor-Oncology) study: implications of P2Y12 inhibition for metastasis and cancer-associated thrombosis. JACC CardioOncol 2 (2), 236–250. doi:10.1016/j.jaccao.2020.04.009
Keywords: drug repurposing, antiplatelet agents, systems biology and network analysis, 5-lipoxygenase, cancer
Citation: Patrignani P, Contursi A, Tacconelli S and Steinhilber D (2024) The future of pharmacology and therapeutics of the arachidonic acid cascade in the next decade: Innovative advancements in drug repurposing. Front. Pharmacol. 15:1472396. doi: 10.3389/fphar.2024.1472396
Received: 29 July 2024; Accepted: 19 August 2024;
Published: 29 August 2024.
Edited by:
Maria Serena Fabbrini, Independent Researcher, Monza, ItalyReviewed by:
Aziz Eftekhari, Joint Ukraine-Azerbaijan research center of nanobiotechnology, AzerbaijanCopyright © 2024 Patrignani, Contursi, Tacconelli and Steinhilber. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Paola Patrignani, ppatrignani@unich.it; Dieter Steinhilber, steinhilber@em.uni-frankfurt.de